Impact of Blood‐Based Biomarkers on Access to Alzheimer's Disease Treatments: A Simulation Study in Japan

The findings suggest that implementing BBM for a triage test demonstrated potential for reducing wait times, particularly in PCP settings. Additionally, utilizing BBM as a confirmatory test can increase the number of treatment-eligible patients, primarily due to increased specialist capacity and decreased diagnostic cost associated with BBM, suggesting that this approach could notably improve access to timely treatment.